CLAIMS

1. Use of a combination of a cyclodextrin compound and budesonide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing neutrophilic inflamantion in a patient suffering from pulmonary inflammatory disease.

2. Use according to Claim 1, in which the cyclodexrin compound and the budesonide are administered respectively at a nominal dosage of about 0.1 mg and about 25 mg/dose.

3. Use according to Claim 1 or 2, in which the cyclodextrin compound delivers the budenoside in a molecular dosage range of from about 0.1 to 500 mg.

4. Use according to Claim 1, 2 or 3, in which the molar ratio between the budenoside and the cyclodextrin compound is from 1:1 to 1:100.

5. Use according to any preceding claim, in which the cyclodextrin compound is hydroxypropyl β-cyclodextrin.

6. Use according to Claim 5, in which the medicament comprises about 250 µg/ml budesonide and about 20 mM HP-β-CD.

7. Use according to Claim 5, in which the medicament comprises about 100 µg/ml budesonide and about 20 mM HP-β-CD.

8. Use according to Claim 5, in which the medicament comprises about 250 µg/ml budesonide and about 10 mM HP-β-CD.

9. Use according to Claim 5, in which the medicament comprises about 100 µg/ml budesonide and about 10 mM HP-β-CD.

10. Use according to Claim 5, in which the medicament is for delivering the budesonide derivative in a molecular dose in a range of from about 50 to about 200 mcg per day.

11. Use according to any preceding claim, in which the medicament comprises a solution having a pH of from about 7 to about 7.5.

12. Use according to Claim 1 or 5, in which the medicament comprises a complex of a budesonide derivative and a cyclodextrin compound in a stoichiometric ratio of about 1:1.

13. Use according to any preceding claim, in which the medicament is capable of decreasing CXCL-1 levels in a host mammal.

14. Use according to any preceding claim, in which the pulmonary inflammatory disease is chronic obstructive pulmonary disease.